Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib may slow the growth of cancer by stopping blood flow to the tumor. Drugs
used in chemotherapy use different ways to stop tumor cells from dividing so they stop
growing or die. Combining chemotherapy and celecoxib may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of celecoxib and docetaxel in treating
patients who have non-small cell lung cancer.